PLYMOUTH, Mass.--(BUSINESS WIRE)--Harvest Technologies Corp. (www.harvesttech.com) announced today that Berthold Amann, MD, a specialist in vascular medicine, presented data (“Autologous Bone Marrow Transplantation for the Induction of Arteriogenesis: A New Treatment for Critical Limb Ischemia”) from a clinical trial under his supervision at the Berlin (Germany) Vascular Center of Franziskus Hospital. He showed the results of 51 patients with end-stage Peripheral Arterial Disease (PAD), so-called Critical Limb Ischemia (CLI). Nearly all of these patients had severe pain at rest and were already scheduled for leg amputation. All surgical and endovascular options for these patients had been previously exhausted. After the injection of a concentrate of the patients’ own bone marrow stem cells, leg amputation could be avoided in more than half of these patients. This is a major success because under normal circumstances, the amputation rate in CLI is 90-100% in this patient population within a year.
